

AD_____

Award Number: DAMD17-99-1-9092

TITLE: Cloning and Characterization of Active Egr-1 Target Genes
by In Vivo Crosslinking

PRINCIPAL INVESTIGATOR: Ian de Belle, Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute
La Jolla, California 92037

REPORT DATE: May 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010810 085

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2001	3. REPORT TYPE AND DATES COVERED Annual Summary (1 May 00 - 30 Apr 01)	
4. TITLE AND SUBTITLE CLONING AND CHARACTERIZATION OF ACTIVE EGR-1 TARGET GENES BY IN VIVO CROSSLINKING			5. FUNDING NUMBERS DAMD17-99-1-9092	
6. AUTHOR(S) Ian de Belle, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Burnham Institute La Jolla, California 92037 Email - idebelle@burnham.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) The purpose of this project is to identify the profile of Egr-1 target genes in breast cells. Normal breast cells are shown to express Egr-1, while breast cancer cells do not. It is, therefore, important to identify the nature of those target genes regulated by Egr-1 which are absent in breast cancer cells. I have approached this goal by performing in vivo crosslinking of Egr-1 to its target sites in breast cells, followed by immunocapture of Egr-1 together with its targets. In this report I have proceeded with the identification, by multiplex PCR amplification, of Egr-1 target genes. Specifically, I have successfully cloned a novel full length cDNA and describe anew Egr-1 target gene called TEX1. Expression of TEX1 has the biological activity of growth inhibition in a cell cycle dependent manner. I am proceeding to further characterize this new gene as well as identifying additional Egr-1 target genes expressed in both normal and breast cancer cells.				
14. SUBJECT TERMS Breast Cancer, Crosslinking, Transcription Factors, Target Gene Identification			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

___ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

___ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

___ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

___ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

___ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

V. A. B. S. S. 5/28/01
PI - Signature Date

Table of Contents

Cover.....	1
SF 298.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5
Body.....	5-8
Key Research Accomplishments.....	8
Reportable outcomes.....	8

Introduction

This report provides a detailed description of my accomplishments for the second year of funding supported by the USAMRMC Breast Cancer Research Program. The subject of my research is to identify and clone target genes for the transcription factor Egr-1. The purpose is to gain an understanding of the profile of genetic targets for Egr-1 in normal breast cells which are absent from breast cancer cells. The long term goal is to build transcriptional profiles for Egr-1 and to identifying key transcriptional defects occurring in breast cancer cells. For this report, the scope of the research is to first confirm the expression of Egr-1 in normal, but not in breast cancer cells. Subsequently, Egr-1 must be crosslinked to its target sites *in vivo* through the action of a buffered formaldehyde solution, and the crosslinked Egr-1, together with its bound DNA, isolated for further characterization.

Body

The results highlighted from the first year documented the successful use of the *in vivo* crosslinking technique to recover DNA targets directly bound by a transcription factor, in this case Egr-1. Additionally, the application of multiplex PCR allowed the amplification of cDNA sequences permitting target gene identification.

In this report, I present data describing my progress in the complex task of identifying target genes through which key Egr-1 regulatory effects result in the maintenance of normal breast cell function.

After successfully multiplex amplification, to achieve completion of the second phase of the project it was critical to determine whether the protocol faithfully accomplished the amplification of genuine Egr-1 target genes. To address this, I proceeded to first isolate individual cDNA's to allow their characterization and sequence identification. During this process, I have sequenced a full length cDNA for which no homolog or ortholog is known, by genomic database searching. I have named this new gene TEX1 for Target of Egr-1 by (X) crosslinking. Therefore, to identify this new gene as a target for Egr-1 transcriptional activity, it was necessary to perform an in depth characterization of the gene. As shown in figure 1, a full length cDNA

was isolated and sequenced. While homology searches of DNA databases revealed no match to the cDNA, I found that the human genome sequencing project was able to map the gene to human chromosome 1. In order to characterize and confirm the regulation of this new gene by Egr-1, I performed both RT-PCR and gel shift experiments. As shown in figure 2, following transfection of Egr-1 into H4 cells (which do not express endogenous Egr-1), a dose dependent induction of the expression of TEX1 was noted. This result indicated that Egr-1 was indeed able to regulate the expression of TEX1 by activating its transcription.

ATG GCG CCG CAG CAG TGA CG AT GG CG CAG TTT CAG GCT CCG CAG CT TCC GA
M A A A D S D D G A V S A P A A S D
CGG TG GT GT CAG CAA AAG CAC A A C A T C T G G G A G G A G C T A G T A G T C C A G G
G G V S K S T T S G E E L V Q
T T C C C G T A G T G A T G T G C A A A G C A A C A C T T C A A G G A G A T G G C C A T C C C
V P V V Q S N N F K E M W P S
T C C T G C T A G C C A T A A G A C A G C T A A T T C G T G G C T G T G G A C A C G G A G C T G A
L L L A T K T A N F V D T
G T G G C T T G G G A C A G G A A G A G T T T G C T G A A C C A G T G C A T T G A G G A A C G T T
S G L G D R K S L L N Q C I E E R
A C A A G G C C G T G T G T C A T G C T G C C A G A C C C G T T C T A T C C T T C C C T G G G C C
Y K A V C H A A R T R S I L S L G
T C G C C T G C T C A A G C G G C A G C C A G A C A A G G T G A A C A T T C C T A T C T G G C T C
L A C F K R Q P D K G E H S V L A
A A G T G T T C A A T C T C A C T C T G C T G T G C A T G A G G A G A T G T C A T A G A A C C A A A
Q V F F N L T L L C M E E V V I E P K
G T C T G T G C A G T C C T G A T A C A G C A T G G C T C A A C T C A A C C A G C A G T A T G C C
S V Q F L I Q H G F N F N Q Q V A
C A A G G C A T C C C T A C C A T A A G G C A A T G A C A A G G G T G A T G A G A G C C A G A G
Q G I E Y H K G N D K G D E S Q S
C C A G T C A G T A C G G A C C C T A T T C C T G G A G C T A A T C C G A G C C C G C G G C C C C T
Q S V R T L F L E L I R A R E L
G G T G C T A C A A T G G C C T T A T A G A C T T G G T T C C T G T A C C A G A A C T C T A T
V L H N G L I D L V F L I C N F Y
G C A C A C T C C C T G A G A G T C T G G A A C C T T C A C C G C T A C C T G T G T G A G A T G
A H L P E S L G T F T A D C E M
T T C C C A G C A G G C A T T A T G A C A C A A A T A T G C T G C T A G T T C A T G C C C G T T
F P A G I Y D T K Y A E F H A R
T C G T G G C C T C C T A C T A G A A T A T G C C T C C G A A A T G T G A A C G G G A A A T G
F V A S S Y L E V A E R K C E F C N
G G A A G C A G C G G G C A G C T G G C A G C C C A C A C C T A C C C T G G A G T T C T G C A A C
G K O R A A A G G S P H L T L E F C N
T A T C C T T C C A G C A T G A G G A C C A T A T T G A T T A C C G C T G C T G C C T G C C C C A
Y P S S M R D H I D Y R C C L P P
G C A A C C C A C C G T C C T C A T C C C A C C A G C A T C T G T G A C A C T T C T G G C T T A T
A T H R P H P T S I C D N F S A V
G G C T G G T G C C C C T G G G A C C A C A G T G T C C T C A G T C T C A G A T A T T G A C C T T
G W C P L G P Q C P Q S H D I D L
A T C A T T G A C A C T G A T G A G G C T G C G G C A G A G G A C A A G C G C G C A C G C G A G G
I I D T D E A A A A E D K R R R R R
A C G T A G G G A A A A C G G A A G A G G C T T T A T G A A C C T A C C G G G A C A C A G A C
R R E K R K R A L L N L P G T Q C
C T C T G G G A A G C T A A G A T G G T C C T C C A A G A A G C A G G T C T G T G G G G A T A
S G E A K D G P P K K Q V C G D
G C A T C A A G C C T G A A G A A C C G A G C A G G A G G T G G C T G C C G A T G A A A C T A G G
S I K P E E T E Q E V A A D E T R
A A C C T G C C T C A C T C C A A G C A A G G C A A C A A A T G A C T A G A G A T G G G A T T
N L P H S K Q G N K N D L E M G I
A A G G C A G C A A G G C C T G A A A T A G C T G A T A G A G C T A C C T C A G A A G T G C C A G G
K A A A R P E I A E R A T S E V P G
G A G C C A A G C C A G T C C T A C C C A G T G C C T G G G G T G G A T T G C A C C G G G C T G
S Q A S P N P V P G G G L H R A
G T T T T G A T G C C T T A T G A C A G G T A T G T G A T G G C C A T G T G A A G T G A G C C A
G F D A F M T G Y V M A Y V E V S Q
G G G A C C G C A A C C C T G C A G C T C T G G A C C C T G G C T C C C T G A A T G C C A C A A T A A
G P Q P C S S G P W L P E C H N K
G G T A T A T T G A T G G C A A A G C T G T A C C C C T C A C A G T G G C C A A G A G C A G T T
V Y L S G K A V P L L T V A K S Q F
C T C T C G T T C C T C C A A G C C C A C A T C A G A A G A T G A A G C T A C T T G G G G C A G
S R S S K A H N Q K M K L T W G S
T A G C T G A
S stop

Figure 1. cDNA and protein sequence of TEX1; a new Egr-1 target gene.




Figure 2. RT-PCR showing activation of TEX1 expression following Egr-1 transfection




Figure 3. Gel shift analysis showing specific binding of Egr-1 to the TEX1 5' non-coding sequence.




Figure 4. TEX1 inhibits cell growth. Growth curves for empty vector (pCEP4), an unrelated protein (calbindin), or cells expressing TEX1 (TEX1), are shown.

Further confirmation that TEX1 represents a direct target of Egr-1 was shown using the gel shift assay. As seen in figure 3, recombinant Egr-1 displayed direct and specific binding to the 5' non-coding portion of the TEX1 gene. Further characterization of TEX1 has included studies examining the biological activity of this newly found protein. I have found that following transfection of a TEX1 expression vector, cell growth is dramatically inhibited (figure 4). This result is currently being further characterized to identify the precise mechanism by which growth inhibition is achieved. Clearly, the cloning of this new gene has potential value to contribute a greater understanding of how the loss of Egr-1 in breast cancer cells contributes to their uncontrolled growth. Together, these results confirm not only the identification of an Egr-1 target gene, but have provided evidence that the crosslinking technology is capable of new gene identification. Having demonstrated the validity of the technology I am continuing with my planned statement of work by screening the captured and amplified cDNAs. To accomplish this task in the most efficient manner, I have applied the technology of DNA microarray screening to allow simultaneous identification of the entire profile of Egr-1 targets. A facility here at the Burnham Institute is in the final stages of set up, and I have been allowed to test the in house produced microarrays for my project. To date my profile of multiplex target have been analyzed three times, and I am in the process of repeating the entire experimental protocol to ensure reproducibility. This is necessary given the variation from array to array that currently exists. I anticipate that the results from the repeat experiments will be concluded shortly, following expansion

of the Institute's facility. This will lead to the compilation of consensus Egr-1 targets in breast cells and be followed by their analysis as detailed in the third phase of this project.

Appendix

1) Key research accomplishments:

- * Use of multiplex PCR amplification to identify a new gene target for Egr-1, named TEX1.
- * Characterization of TEX1 as a genuine direct target for Egr-1, validating the technology.
- * Identification of TEX1 as an inhibitor of cell growth.
- * Application of DNA microarray screening to profile captured Egr-1 targets simultaneously.

2) Reportable outcomes:

Manuscript: I. de Belle, J.-X. Wu, S. Sperandio, D. Mercola and E.D. Adamson (2001). In vivo cloning and characterization of a new growth suppressor protein TEX1: a direct target gene of Egr-1 (manuscript in preparation).

Funding received: University of California, Tobacco related diseases research program. New Investigator Award 9KT-0078. Start date, July 2000.